Liver Cancer Therapeutics Market to Reach USD 15.69 Billion by 2032 | CAGR 19.21% (2024-2032)
The Liver Cancer Therapeutics Market was valued at USD 3.12 billion in 2023 and is projected to reach USD 15.69 billion by 2032, growing at a CAGR of 19.21% from 2024 to 2032. This market growth is driven by the increasing global incidence of liver cancer, fuelled by factors such as chronic hepatitis B and C infections, alcohol use, and non-alcoholic fatty liver disease. Recent advancements in therapeutic approaches, particularly immunotherapies and combination regimens, are significantly improving patient survival and treatment outcomes.